CLOs on the Move

Regenxbio

www.regenxbio.com

 
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO`s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO`s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO`s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.regenxbio.com
  • 9804 Medical Center Drive
    Rockville, MD USA 20850
  • Phone: 240.552.8181

Executives

Name Title Contact Details
Nina Hunter
 VP, Regulatory and Science Profile
Crystal Suri
 Executive Director, Intellectual Property Profile
Patrick Christmas
 Senior Vice President, General Counsel and Secretary Profile
Lisa Carlton
 Vice President, Global Regulatory Affairs Profile

Similar Companies

Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.

BioSciConcepts

BioSciConcepts is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cradle Genomics

At Cradle Genomics, our mission is to provide knowledge that helps every pregnancy.

Bioo Scientific

Bioo Scientific is a Austin, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Relay Therapeutics

Relay Therapeutics is building the world`s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. By placing protein motion at the heart of drug discovery, Relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. Headquartered in Cambridge, Mass., Relay Therapeutics is a private company launched in 2016. To date, Relay Therapeutics has raised $120M in financing from Third Rock Ventures, BVF Partners, GV (formerly Google Ventures), an affiliate of D.E. Shaw Research, Casdin Capital, EcoR1 Capital, Section 32 and Alexandria Venture Investments. Our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you`re creative, collaborative and passionate about making a difference in the lives of patients, join us!